IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
出版年份 2020 全文链接
标题
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
作者
关键词
-
出版物
Future Oncology
Volume 16, Issue 15, Pages 975-989
出版商
Future Medicine Ltd
发表日期
2020-05-01
DOI
10.2217/fon-2020-0162
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
- (2019) Gao-Min Liu et al. Cancer Cell International
- Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy
- (2019) Zachary J. Brown et al. HEPATOLOGY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities
- (2019) Chen Lu et al. Molecular Cancer
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA39Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
- (2019) M Lee et al. ANNALS OF ONCOLOGY
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
- (2019) Marc Hilmi et al. Journal for ImmunoTherapy of Cancer
- The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: A systematic review and meta-analysis
- (2019) Xinyu Zhang et al. PLoS One
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis
- (2018) Lei Liang et al. HPB
- The immune contexture of hepatocellular carcinoma predicts clinical outcome
- (2018) Friedrich Foerster et al. Scientific Reports
- Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
- (2018) Jian Zhou et al. Liver Cancer
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Characteristics of Early Recurrence After Curative Liver Resection for Solitary Hepatocellular Carcinoma
- (2018) Sung-Mi Jung et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
- (2018) Anthony W.H. Chan et al. JOURNAL OF HEPATOLOGY
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients
- (2018) Zhen-Li Li et al. EJSO
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- AASLD guidelines for the treatment of hepatocellular carcinoma
- (2017) Julie K. Heimbach et al. HEPATOLOGY
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- (2017) Masao Omata et al. Hepatology International
- Circulating CD14+ HLA-DR−/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery
- (2017) Xing-Hui Gao et al. HEPATOLOGY RESEARCH
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis
- (2017) Lejia Sun et al. Oncotarget
- Medical Management of Hepatocellular Carcinoma
- (2017) Nicole E. Rich et al. Journal of Oncology Practice
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
- (2016) A. Gabrielson et al. Cancer Immunology Research
- PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment
- (2016) Tomoaki Iwata et al. Scientific Reports
- A Comparison of the Surgical Outcomes Among Patients With HBV-positive, HCV-positive, and Non-B Non-C Hepatocellular Carcinoma
- (2015) Tohru Utsunomiya et al. ANNALS OF SURGERY
- Recurrence of Hepatocellular Cancer After Resection
- (2015) Parissa Tabrizian et al. ANNALS OF SURGERY
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
- (2015) Joon Hyeok Lee et al. GASTROENTEROLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Hepatic Resection as a Safe and Effective Treatment for Hepatocellular Carcinoma Involving a Single Large Tumor, Multiple Tumors, or Macrovascular Invasion
- (2015) Jian-Hong Zhong et al. MEDICINE
- Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma
- (2014) Thomas Yau et al. GASTROENTEROLOGY
- BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group
- (2014) Fabio Farinati et al. LIVER INTERNATIONAL
- Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence
- (2014) Li-Chun Lu et al. SEMINARS IN LIVER DISEASE
- Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review
- (2014) Jian-Hong Zhong et al. TUMOR BIOLOGY
- Roles of Tregs in development of hepatocellular carcinoma: A meta-analysis
- (2014) Hong-Qiang Zhao WORLD JOURNAL OF GASTROENTEROLOGY
- A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers
- (2013) Guido Torzilli et al. ANNALS OF SURGERY
- Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
- (2013) Fumitaka Arihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality
- (2013) S. Kalathil et al. CANCER RESEARCH
- Combination of Intratumoral Invariant Natural Killer T Cells and Interferon-Gamma Is Associated with Prognosis of Hepatocellular Carcinoma after Curative Resection
- (2013) Yong-Sheng Xiao et al. PLoS One
- Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria
- (2012) K.-C. Lim et al. BRITISH JOURNAL OF SURGERY
- Impairment of CD4+cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma
- (2012) Junliang Fu et al. HEPATOLOGY
- Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma
- (2012) Eishiro Mizukoshi et al. HEPATOLOGY
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages
- (2012) Daria Capece et al. Biomed Research International
- Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis
- (2011) Le Li et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- High Expression of Macrophage Colony-Stimulating Factor in Peritumoral Liver Tissue Is Associated With Poor Survival After Curative Resection of Hepatocellular Carcinoma
- (2008) Xiao-Dong Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started